Trial Profile

A Phase 1/2, First-in-Human Study of VNX-202 Gene Therapy in Patients With HER2-Positive Cancer

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 14 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs VNX 202 (Primary)
Indications Advanced breast cancer; Cancer; Early breast cancer; Gastric cancer; HER2 positive breast cancer; Solid tumours
Focus Adverse reactions; First in man
Acronyms SENTRY-HER2
Sponsors Vironexis Biotherapeutics

Most Recent Events

01 Oct 2025 Status changed from not yet recruiting to recruiting.
25 Sep 2025 Status changed from planning to not yet recruiting.
19 Sep 2024 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com